title: Mitoxantrone and VP-16 in refractory acute myelogenous leukemia.
authors.forename: A D
authors.initials: AD
authors.lastname: Ho
authors.forename: T
authors.initials: T
authors.lastname: Lipp
authors.forename: G
authors.initials: G
authors.lastname: Ehninger
authors.forename: P
authors.initials: P
authors.lastname: Meyer
authors.forename: M
authors.initials: M
authors.lastname: Freund
authors.forename: H J
authors.initials: HJ
authors.lastname: Illiger
authors.forename: M
authors.initials: M
authors.lastname: Körbling
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D004334:Drug Administration Schedule; D005047:Etoposide / Q000008:administration & dosage; D005260:Female; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D008942:Mitoxantrone / Q000008:administration & dosage; D012074:Remission Induction
chemical_list: D005047:Etoposide; D008942:Mitoxantrone